Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT07493512
Phase
PHASE1
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Xaluritamig
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Denver, Colorado, United States|39.73915,-104.9847
  • Denver, Colorado, United States|39.73915,-104.9847
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenocarcinoma with neuroendo…
  • mCRPC with ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scintigraphy imagi…
  • Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
  • Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start v…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →